Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

Grey Matters Improves Warrant Terms of Private Placement

Grey Matters Amends Warrant Terms to Secure Financing as Clinic Expansion Nears; Stock Holds Near Issue Price

By The Northwire Desk — AI Analysis May 25, 2026 · 07:00 GREY · 0.4 Grey Matters Health Inc.
Executive Summary
  • Grey Matters Health Inc. amended terms of a CAD $1,000,000 non-brokered private placement announced on April 22, 2026.
  • The amendment removes the warrant acceleration feature (previously triggered if share price exceeded CAD $0.80 for 10 consecutive days).
  • Warrant exercise period extended from 24 months to 36 months from issuance date.
  • Offering details remain: CAD $0.40 per Unit, consisting of one Class A common share and one Common Share purchase warrant.
  • Warrant exercise price set at CAD $0.60 per Warrant Share.
  • Proceeds earmarked for advancing the Alzheimer’s Disease program and establishing the first U.S. neuroimaging clinic (Davie, FL).
  • Company also signed a non-binding LOI with Catalyst MedTech on May 20, 2026, for minimum 200 brain PET scans at the planned Tampa location.
Material Impact
  • The news is an administrative amendment to a financing deal already announced and priced into the market weeks prior (April 22).
  • Removing the acceleration clause has minimal immediate financial impact as the current share price ($0.40) is significantly below the trigger price ($0.80), making the clause dormant regardless of the change.
  • Extending warrant expiry from 2 to 3 years increases long-term dilution risk for existing shareholders, which is a negative structural factor masked by positive financing news.
  • The amendment likely facilitates the closing of the $1M raise by making terms more attractive to investors given the stock's decline from $0.95 to $0.40.
  • No new revenue streams or clinical breakthroughs are announced; this is purely capital structure management.
  • Given the small size of the raise ($1M CAD) relative to clinic build-out costs, the materiality on operational progress is limited but necessary for survival.
GREY · Price
Company Overview
  • Flagship Project: NovaScan Neuroimaging Clinics™ specializing in Alzheimer’s Disease detection using FDA-cleared CareMiBrain system.
  • Technology: Stand-alone diagnostic brain PET scanner reducing radiation by 25% compared to conventional systems; open upright environment for patient comfort.
  • Locations: Davie, FL (inaugural clinic planned Q3 2026) and Tampa, FL (second location planned end of Q4 2026).
  • Business Model: Revenue from direct physician referrals and large-scale CRO services agreements (e.g., Catalyst MedTech trial scans).
Read the original news release →

More from Grey Matters Health Inc.

Jun 05, 2026 · 16:01

Grey Matters Health Secures $500K Tranche as Florida Neuroimaging Clinics Edge Closer to Opening

Financings May 20, 2026 · 07:00

Grey Matters Health Signs LOI for Tampa Trial, Yet Dilution and Timeline Risks Persist

Other Apr 22, 2026 · 07:00

Grey Matters Health Raises Capital at Discount to Fund US Clinic Expansion Amidst Dilution Concerns

Financings